New Key Statistics Module, Z-Score and F-Score
NAS:TRDA Key Ratios
| Market Cap $ M | 477.01 |
| Enterprise Value $ M | 216.03 |
| P/E(ttm) | 22.43 |
| PE Ratio without NRI | 22.43 |
| Forward PE Ratio | 2,500.00 |
| Price/Book | 1.76 |
| Price/Sales | 2.97 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 162.00 |
| EPS (TTM) $ | 0.63 |
| Beneish M-Score | 4.15 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | 9.10 |
| EV-to-EBITDA | 8.01 |
| PEG | -- |
| Shares Outstanding M | 33.76 |
| Net Margin (%) | 14.42 |
| Operating Margin % | 14.57 |
| Pre-tax Margin (%) | 24.87 |
| Quick Ratio | 2.38 |
| Current Ratio | 2.38 |
| ROA % (ttm) | 4.82 |
| ROE % (ttm) | 9.83 |
| ROIC % (ttm) | 5.94 |
| Dividend Yield % | -- |
| Altman Z-Score | 1.86 |
TRDA Number of Guru Trades
TRDA Volume of Guru Trades
Gurus Latest Trades with NAS:TRDA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:TRDA is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Entrada Therapeutics Inc Insider Transactions
No Available Data
News about NAS:TRDA
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers